Open AccessPertuzumab (Perjeta)
Author(s) -
Reimbursement Team
Publication year - 2022
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2022.320
Subject(s) - pertuzumab , reimbursement , trastuzumab , medicine , breast cancer , oncology , family medicine , cancer , political science , health care , law
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses pertuzumab (Perjeta), 420 mg/14 mL vial for IV infusion.
Indication: In combination with trastuzumab and chemotherapy for neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either > 2 cm in diameter or node-positive).